20 set - Italia
Alnylam Pharmaceuticals
Our client is Alnylam Pharmaceuticals (Nasdaq: ALNY), a leading biopharmaceutical company that has pioneered the translation of RNA interference (RNAi) into a new class of innovative medicines, with the potential to transform the lives of patients affected by rare and more prevalent diseases.
Founded in 2002 and built on Nobel Prize-winning science, Alnylam has led the RNAi Revolution by developing clinically validated therapies that target diseases at their genetic source,
21 set - Firenze
randstadintempo
21 set - Catania
OVER
21 set - Venezia
Marina Scafoclub
21 set - Piemonte
Teoresi Group